This study develops lipid nanoparticle-encapsulated mRNA-encoding antibodies (mRNab-LNPs) targeting CD19, demonstrating robust anti-CD19 antibody production in vivo. Intramuscular injection of mRNab-LNPs reduces CD19+ B and plasma cells in lupus and rheumatoid arthritis mice, significantly alleviating histopathological changes and tissue injuries of skins, kidneys, and joints. These findings highlight the therapeutic and translational potential of mRNab-LNPs for treating refractory autoimmune diseases.
Abstract
The hyperactivation of autoreactive B cells and plasma cells leads to the development of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), therefore, targeting the abnormal B cells and plasma cells might hold promise for the treatment of these refractory and relapsing diseases. This study developed lipid nanoparticle-encapsulated mRNA-encoding antibodies (mRNab-LNPs) targeting CD19, and evaluated their therapeutic efficacy in lupus and RA mice. mRNab-LNPs enabled robust production of anti-CD19 antibodies in multiple cell lines in vitro. Interestingly, intramuscular injection of mRNab-LNPs resulted in high and sustained production of anti-CD19 antibodies in mice. In particular, the numbers of CD19+ circulating B cells and tissue-resident plasma cells are significantly reduced by mRNab-LNPs in mice. As a result, mRNab-LNPs significantly reduced the histopathological changes and tissue injuries in both lupus and RA mice. Collectively, these findings demonstrate the therapeutic and translational potential of mRNab-LNPs in the treatment of SLE and RA.
Advanced Science, EarlyView. Read More
